Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

By C. Lawton. 2011

735 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/31eeb7641c103e116babd0b96888f6837ad42c19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Senkus
2. F. Cardoso
3. S. Kyriakides
4. W. Wood
5. F. Penault-Llorca
6. A. Giuliano
7. S. Ohno
8. S. Loibl

Citations in the corpus

• Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer (2014, result): “Two large randomized trials have now reported comparable long-term efficacy and toxicity data with this approach, establishing it as an acceptable alternative.(44,45) In general, the studies evaluating these approaches did not specify particular surgical margin widths and required only complete micr”
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “66 Gy single dose) have shown similar effectiveness and comparable side effects [90] [I, B], but caution is needed in patients with G3 differentiated tumors, in young patients and in patients with mastectomy and/or additional regional irradiation, as these patients were either not included or were u”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Hypofractionated shorter course radiotherapy has become accepted as a standard option [11, 12] offering increased patient convenience and reduced resource usage.”
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, unknown): “Radiation therapy—abbreviated (hypofractionated or accelerated) whole breast Long-term results of the Canadian randomized trial in pT1,2 N0 patients largely treated without adjuvant chemotherapy at a median follow-up of 12 years show similar locoregional control, survival, tolerability, and cosmesis”
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013, background): “Two large studies [68, 69] support the safety and efficacy of shorter courses of whole breast radiation therapy (40 Gy in 15 or 42.”